Long-Term Hematologic, Infectious, Critical Illness, and Survival Outcomes With JAK Inhibitors Versus TNF Inhibitors in Autoimmune Rheumatologic Diseases: A Multi-Year Propensity-Matched Real-World Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1412; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "TNFi included adalimumab, etanercept, golimumab, certolizumab pegol, and infliximab; JAKi included tofacitinib, baricitinib, upadacitinib, and filgotinib. These findings characterize a clinically meaningful long-term safety phenotype associated with JAKi that extends beyond known cardiovascular and thromboembolic signals – encompassing hematologic suppression, heightened infection severity, and excess critical illness risk that widens progressively over time. This does not negate the established efficacy of JAKi or their role in patients with inadequate TNFi response; rather, it defines a safety landscape that should actively inform patient selection and monitoring intensity. Clinicians prescribing JAKi to patients with baseline hematologic vulnerability, recurrent infections, or significant comorbidity burden should integrate structured CBC surveillance and infection mitigation into long-term management plans."
Clinical • Real-world • Real-world evidence • Ankylosing Spondylitis • Axial Spondyloarthritis • Cardiovascular • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Arthritis • Leukopenia • Lupus • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Psoriatic Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Septic Shock • Seronegative Spondyloarthropathies • Sjogren's Syndrome • Solid Organ Transplantation • Systemic Lupus Erythematosus
|
|
Riya Shah1; Jatin Thukral2; Pyush Moudgil3; Freya Shah4; Aysal Mahmood5; Maania Naseem6; Saourabh Rajesh Desai7; Syeda Sayeed8
|